High Cholesterol

Clinical Trial Finder

Many patients with high cholesterol are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Administered Alirocumab in Healthy Chinese Subjects

Condition:   Hypercholesterolemia
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Drug: placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified December 2016

Lp(a) and Aortic Valve Calcification

Condition:   Heterozygous Familial Hypercholesterolemia
Intervention:  
Sponsors:   Laval University;   Amgen
Not yet recruiting - verified November 2016

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

Condition:   Hypercholesterolemia
Interventions:   Drug: Praluent (Alirocumab);   Drug: Placebo
Sponsors:   Regeneron Pharmaceuticals;   Sanofi
Recruiting - verified November 2016

Comprehensive Treatment of Angina in Women With Microvascular Dysfunction

Conditions:   Angina Pectoris;   Coronary Microvascular Disease
Interventions:   Dietary Supplement: Diet;   Behavioral: Training;   Drug: Medication (with statin and ACE-inhibition)
Sponsors:   Bispebjerg Hospital;   University Hospital Bispebjerg and Frederiksberg;   Cambridge Weight Plan Limited
Not yet recruiting - verified November 2016

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Condition:   Hypercholesterolaemia
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Drug: statins;   Drug: ezetimibe;   Drug: cholestyramine;   Drug: fenofibrate;   Drug: omega-3 fatty acids;   Drug: nicotinic acid
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified November 2016

Chart Review of Repatha® in Subjects With Hyperlipidaemia

Condition:   Hypercholesterolaemia
Intervention:  
Sponsor:   Amgen
Recruiting - verified November 2016

A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)

Conditions:   Hypercholesterolemia;   Familial Hypercholesterolemia
Interventions:   Drug: Ezetimibe;   Drug: Rosuvastatin
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified November 2016

Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia

Condition:   Hypercholesterolemia
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Drug: placebo for alirocumab;   Drug: ezetimibe;   Drug: placebo for ezetimibe;   Drug: atorvastatin;   Drug: rosuvastatin;   Drug: simvastatin
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified November 2016

Text Messaging to Promote Walking Among Latino Adults at Risk for Peripheral Arterial Disease

Condition:   Peripheral Arterial Disease
Interventions:   Other: Text Messages;   Other: Phone Calls;   Other: Handout
Sponsors:   University of Kansas Medical Center;   National Institute on Aging (NIA)
Active, not recruiting - verified November 2016

Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin

Condition:   Hypercholesterolaemia
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Drug: placebo;   Drug: atorvastatin;   Drug: fenofibrate;   Drug: bezafibrate;   Drug: ezetimibe
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Active, not recruiting - verified November 2016

Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World Setting

Condition:   Coronary Artery Disease, Hypercholesterolemia, Hypertension
Intervention:   Other: No intervention
Sponsor:   Pfizer
Recruiting - verified November 2016

Effect of Simvastatin Withdrawal on Ocular Endothelial Function

Condition:   Healthy
Interventions:   Device: Dynamic Vessel Analyzer (DVA);   Device: Laser Doppler Velocimetry (LDV);   Drug: Simvastatin;   Other: Placebo
Sponsor:   Medical University of Vienna
Not yet recruiting - verified December 2016

A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)

Conditions:   Hypercholesterolemia;   Heterozygous Familial Hypercholesterolemia
Interventions:   Drug: EZ 10 mg/Atorva 20 mg FDC;   Drug: EZ 10 mg/Atorva 10 mg FDC
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified November 2016

A Study to Evaluate the Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia

Condition:   Homozygous Familial Hypercholesterolemia (HoFH)
Intervention:   Drug: Rosuvastatin 20mg
Sponsor:   AstraZeneca
Completed - verified November 2016

Study of Glycogen Storage Disease Expression in Carriers

Condition:   Glycogen Storage Disease
Intervention:   Genetic: Glycogen Storage Disease markers
Sponsor:   University of Florida
Completed - verified December 2016

A Toolbox Approach to Obesity Treatment in Primary Care

Condition:   Obesity
Interventions:   Behavioral: Commercial weight loss program;   Behavioral: Colorado Weigh;   Dietary Supplement: Meal replacements;   Drug: Obesity pharmacotherapy;   Behavioral: Recreation center passes
Sponsor:   Denver Health and Hospital Authority
Active, not recruiting - verified November 2016

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Condition:   Dyslipidemia
Interventions:   Biological: Evolocumab (AMG 145);   Other: Placebo;   Drug: Effective statin therapy
Sponsor:   Amgen
Completed - verified November 2016

Effect of the Consumption of a Fermented Milk Enriched With Plant Sterols (Italy)

Condition:   Mildly Hypercholesterolemic Subjects
Interventions:   Other: 1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).;   Other: 2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters
Sponsor:   Danone Research
Completed - verified November 2016

Effects of Fermented Milk Product Enriched With Plant Sterols and Policosanols in Mild Hypercholesterolaemic Adults

Condition:   Mildly Hypercholesterolemic Subjects
Interventions:   Other: 1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 10 mg of policosanols per unit;   Other: 2- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 20 mg of policosanols per unit;   Other: 3- Low fat drinkable fermented dairy product with 1.6g of plant sterol (as free equivalent) but without policosanols (Active control)
Sponsor:   Danone Research
Completed - verified November 2016

Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)

Conditions:   Hyperlipoproteinemia Type II;   Heterozygous Familial Hypercholesterolemia
Interventions:   Drug: Anacetrapib;   Drug: Placebo for Anacetrapib
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified November 2016

Lipoic Acid and Prevention of Heart Disease

Condition:   Atherosclerosis
Interventions:   Dietary Supplement: R-alpha lipoic acid;   Dietary Supplement: Placebo
Sponsors:   Oregon State University;   Oregon Health and Science University;   National Center for Complementary and Integrative Health (NCCIH)
Active, not recruiting - verified November 2016

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Conditions:   Atherosclerosis;   Cardiovascular Diseases;   Hypercholesterolemia;   Hypertension;   Diabetes Mellitus, Type 2;   Diabetes Mellitus;   Coronary Disease
Interventions:   Drug: Anti-hyperglycemic Agents;   Drug: Anti-hypertensive Agents;   Drug: Blinded fenofibrate or placebo plus simvastatin
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institute on Aging (NIA);   National Eye Institute (NEI);   Centers for Disease Control and Prevention
Completed - verified November 2014